NCT06031441 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Locally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

RO7566802

RO7566802 solution for infusion will be administered as specified in each treatment arm.

DRUG

Atezolizumab

Atezolizumab solution for infusion will be administered as specified in each treatment arm.

Trial Locations (11)

2010

RECRUITING

St Vincent's Hospital Sydney, Darlinghurst

3000

RECRUITING

Peter Maccallum Cancer Centre, Melbourne

10029

RECRUITING

Icahn School of Medicine at Mount Sinai (ISMMS), New York

35233

RECRUITING

University of Alabama at Birmingham (UAB), Birmingham

37203

RECRUITING

SCRI Oncology Partners, Nashville

06520

RECRUITING

Yale Cancer Center, New Haven

V5Z 4E6

RECRUITING

British Columbia Cancer Agency - 600 10th Ave W, Vancouver

M5G 1Z5

RECRUITING

Princess Margaret Cancer Centre, Toronto

EC1A 7BE

RECRUITING

St Bartholomew's Hospital, London

W1G 6AD

RECRUITING

Sarah Cannon Research Institute, London

SM2 5PT

RECRUITING

The Royal Marsden hospital, Sutton